MIR, BWXT and GEV delivered upbeat Q2 results and raised outlooks, fueling optimism for nuclear energy OEMs in the AI-driven power boom.

Coterra Energy delivered strong Q2 free cash flow and production, overcoming lower commodity prices and operational setbacks in its Harkey wells. Operational resilience, cost discipline, and robust hedging offset challenges, positioning CTRA for higher production and free cash flow in 2025-2026. Favorable natural gas storage and regional supply dynamics support a bullish outlook for CTRA's gas-weighted portfolio heading into winter.

Shares of Palantir Technologies Inc. (NASDAQ:PLTR) lost 5.06% over the past five trading sessions.

Energi to acquire 51% of Tembo with VivoPower continuing to hold a significant shareholding in Tembo post-SPAC merger Energi is supportive of Tembo's business combination with Cactus Acquisition Corp 1 Limited (“SPAC”) at an equity valuation of $838 million Tembo can now resume finalizing and filing the F-4 SPAC Registration Statement LONDON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR) (“VivoPower” or the “Company”) today announced it has reached agreement with Energi Holdings Limited (“Energi”) whereby Energi will proceed to secure a 51% shareholding in Tembo e-LV B.V. (“Tembo”) via a strategic PIPE investment at the previously …

The Home Depot, Inc. HD will release earnings results for the second quarter, before the opening bell on Tuesday, Aug. 19.

I am initiating coverage of KCE with a Buy rating, expecting continued outperformance vs. the S&P 500. SPDR S&P Capital Markets ETF's strong historical returns are impressive, especially given its focus on financials and lack of mega-cap tech exposure. The ETF is well-diversified, with 62 holdings across a number of subsectors.

Last week, the S&P 500 experienced a rally that took it to three consecutive record highs. But the momentum cooled as economic data painted a complex picture.

Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur [email protected] Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. …

ENGLEWOOD, Colo. , Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company.

Not all REITs are worth buying. Some of the most popular REITs are also the least attractive. I highlight one very overrated REIT and a better alternative.

Move Strengthens Strategic Ties with the Association for Uncrewed Vehicle Systems International and Advances Trusted Operator Initiatives Move Strengthens Strategic Ties with the Association for Uncrewed Vehicle Systems International and Advances Trusted Operator Initiatives

ROLLING MEADOWS, Ill. , Aug. 18, 2025 /PRNewswire/ -- Arthur J.

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- July 9, 2025 -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Centene Corporation ("Centene" or "the Company") (NYSE: CNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 12, 2024 and June 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 8, 2025.

NEW YORK--(BUSINESS WIRE)--MediaCo's Trailblazer Brian Fisher elevated to Chief Revenue Officer.

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone.

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Petco Health and Wellness Company, Inc. ("Petco" or "the Company") (NASDAQ: WOOF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 14, 2021 and June 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 29, 2025.

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Petco Health and Wellness Company, Inc. ("Petco" or "the Company") (NASDAQ: WOOF) for violations of securities laws. Shareholders who purchased the Company's securities between January 14, 2021 and June 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 9, 2025.

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, September 27 – October 1, Amsterdam, The Netherlands. The Company will also host an Industry Evening Mini Symposium titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis” at the meeting. ERS Congress 2025.

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) in the American Journal of Managed Care reinforcing the clinical superiority of the Zio® long-term continuous monitoring (LTCM) service.